Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia

NCT07269210 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07269210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Recruiting
Start date
December 8, 2025
Completion date
August 31, 2027
Enrollment
60 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

severe hypertriglyceridemia